Literature DB >> 3768079

[The percutaneous absorption of diclofenac].

W Riess, K Schmid, L Botta, K Kobayashi, J Moppert, W Schneider, A Sioufi, A Strusberg, M Tomasi.   

Abstract

The percutaneous absorption of diclofenac diethylammonium 1.16% (w/w) in a combination of emulsion cream and gel (Voltaren Emulgel) and of diclofenac sodium 1% (w/w) in a cream formulation (Voltaren cream) was investigated in guinea-pig, rabbit and man. The percutaneous absorption of diclofenac sodium in guinea-pig was 3 to 6% of the dose when the cream formulation in doses of 320, 100 or 40 mg was applied on 10 cm2 of occluded skin and left in place for 6 h. The transdermal delivery of 14C-labelled diclofenac yielded plateau plasma concentrations of radiotracer from 1.5 h after application until removal of the residual cream. Subsequently the steady state drug depots in the skin and muscle tissue were depleted promptly. During daily administration the steady state levels in the muscle tissue in proximity to the application site were about 3 times higher than in distant muscle tissue. By topical application on knee joints of rabbits diclofenac penetrated into the patellar ligament, the adipose corpus and the synovial fluid. In man the percutaneous absorption was 6% of the dose when the Emulgel formulation was spread by 5 mg/cm2 and left for 12 h on non-occluded skin. The pattern of metabolites of diclofenac in human urine was the same after topical and oral administration. In man, upon daily topical administration of 3 times 2.5 g cream formulation (10 mg/cm2) the diclofenac steady state plasma levels were 20 to 40 nmol/l.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768079

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  18 in total

Review 1.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Percutaneous absorption of topically applied NSAIDS and other compounds: role of solute properties, skin physiology and delivery systems.

Authors:  M S Roberts; S E Cross
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

3.  Transcutaneous absorption of naproxen gel.

Authors:  F A van den Ouweland; P C Eenhoorn; Y Tan; F W Gribnau
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application.

Authors:  P Singh; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

5.  A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site.

Authors:  M S Roberts; S E Cross
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

Review 6.  Topical NSAIDs for musculoskeletal conditions. A review of the literature.

Authors:  J H Vaile; P Davis
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

7.  Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease.

Authors:  J Radermacher; D Jentsch; M A Scholl; T Lustinetz; J C Frölich
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

8.  Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial.

Authors:  Turgay Efe; Ercan Sagnak; Philip P Roessler; Alan Getgood; Thilo Patzer; Susanne Fuchs-Winkelmann; Christian D Peterlein; Markus D Schofer
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-01-22       Impact factor: 4.342

9.  Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema.

Authors:  J-L Magnette; J-L Kienzler; D Sallin; C Ménart; F Nollevaux; A Knops
Journal:  Eur J Clin Pharmacol       Date:  2004-09-29       Impact factor: 2.953

Review 10.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.